Skip to main content
CLDX logo

CLDX · Celldex Therapeutics, Inc.

Track CLDX — free
$27.60 +0.05 (+0.18%)
Market Cap
$2.20B
Shares
78.55M
Volume · Nov 19 750.12K Avg daily vol (3M) 1.32M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.96 Open$27.82 Day$27.16–28.54 52W close$22.58–44.87 Avg vol 30d947K Short int9.9M · 12.7% of shares · 10.4d Short vol54% Last earningsSep 22, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 9, 2028 Est · unconfirmed · in 64 wks
call held Feb 28, 2022

Latest documents

2026
Nov 5
Registration statement S-3ASR
Registers shelf for multiple securities offerings

Celldex Therapeutics, Inc. may offer common stock, preferred stock, warrants, depositary shares and units from time to time, with specific offering terms and net proceeds to be specified in prospectus supplements.

Read from the first part of this long document
2 source passages
Celldex Therapeutics, Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination of: • our common stock, • our preferred stock, which we may issue in one or more series, • warrants, • depositary shares, and • units. Our net proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Phase 3 CSU trials meet endpoints, supporting 2027 BLA plan

Celldex Therapeutics, Inc. reported that two Phase 3 barzolvolimab studies in CSU met primary and all key secondary endpoints, with 1,939 patients enrolled; it plans to submit a BLA to the FDA in 2027.

Net loss $75.56M Diluted EPS -$0.96
Read from the MD&A section
3 source passages
In September 2026, we reported positive topline data from the Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab, which met primary and all key secondary endpoints. 1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU. Based on these results, we plan to submit a BLA to the FDA in 2027. Open the document at this passage
Nov 5
Current report 8-K
Barzolvolimab CSU trials meet endpoints; BLA planned for 2027

Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 met primary and key secondary endpoints, supporting barzolvolimab in CSU, with a BLA submission planned for 2027. Celldex Therapeutics reported $650.3 million in cash, cash equivalents and marketable securities, funding planned operations through 2028.

Financial results
6 source passages
Celldex Therapeutics, Inc. In September 2026, the Company reported best-in-disease topline results from the Phase 3 EMBARQ-CSU1 and -CSU2 studies of barzolvolimab in patients with CSU whose symptoms are inadequately controlled by H1-antihistamines. The primary and all key secondary endpoints across both studies and both dose groups were met. Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027. Cash, cash equivalents and marketable securities as of September 30, 2026 were $650.3 million compared to $717.6 million as of June 30, 2026. Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028. Open the document at this passage
Sep 22
Current report 8-K
Other events

Celldex reported that barzolvolimab met primary and all key secondary endpoints at 12 weeks in two Phase 3 chronic spontaneous urticaria trials, with favorable safety through 24 weeks and a planned FDA BLA submission in 2027.

Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $22K ▼ 97.0% Net loss $73.5M Diluted EPS -$0.94
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$157,000
Trailing 12 months
Net income (TTM)
−$309.06M
Trailing 12 months
Revenue growth YoY
-78.0%
Year over year
Operating margin
-213,033.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-12.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$650.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.2%
Year over year · more shares
Price change (1Y)
+7.7%
Trailing year
Short interest
12.7%
Latest settlement · 10.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −15%
below
Price vs 50-day avg −10%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 24%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Weak
1-month return −3%
trailing
6-month return −7%
trailing
YTD return +3%
this year
Relative strength −2%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $31 › 200d $33 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.65% of shares out · ▲ +3.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
254 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Fair
Revenue growth +88%
Y/Y
EPS growth −59%
Y/Y
Free cash flow $-213.7M
Balance sheet $28.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 52%
annualized · 1-yr
Max drawdown −39%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−15% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
24% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $31 › 200d $33 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.65% of shares out · ▲ +3.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
254 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $23 Now $28 · 24% Range high $45
vs 200-day avg -15% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Patients enrolled in EMBARQ-CSU1 and EMBARQ-CSU2 1,939 second quarter ended June 30, 2026 —
Shares outstanding 78.5M second quarter ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLDX
Celldex Therapeutics, Inc.
this stock
$2.20B +2.9% +87.8% — 12.7%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
254
% held
114.0%
Net QoQ
+4.5M sh
Top holder
WELLINGTON MANAGEMENT GRO…
Held Float
View
Held by Funds
Fund positions
256
View
Short & Settlement
Short Interest Rising
Shares short
9.9M
Days to cover
10.4d
Change
+337.8K sh
View
Short Volume
Short vol %
54%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
503
Value
$14.9K
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
42.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.5M
Net income (FY)
$-258.8M
EPS diluted
$-3.90
View
Filings
SEC Filings
Latest
S-3ASR
Filed
Nov 5, 2026
This year
16

Celldex Therapeutics, Inc. may offer common stock, preferred stock, warrants, depositary shares and units from time to time, with specific offering terms and net proceeds to be specified in prospectus supplements.

View
Proposed Sales
Value
$121.2K
Shares
4.2K
Filed
Dec 4, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Celldex Reports Third Quarter Fin…
Published
Nov 5, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CLDX -2.0% -3.5% -7.2% -7.1% +3.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +3.5% +2.8% -1.6% -1.8% -2.0%
Key facts CIK 744218 CUSIP 15117B202 13F (30d) 268 filings 239 filers Visit website Investor relations